DE602007013248D1 - Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie - Google Patents

Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Info

Publication number
DE602007013248D1
DE602007013248D1 DE602007013248T DE602007013248T DE602007013248D1 DE 602007013248 D1 DE602007013248 D1 DE 602007013248D1 DE 602007013248 T DE602007013248 T DE 602007013248T DE 602007013248 T DE602007013248 T DE 602007013248T DE 602007013248 D1 DE602007013248 D1 DE 602007013248D1
Authority
DE
Germany
Prior art keywords
expression
mycobacteriant
hypoxia
application
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013248T
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Publication of DE602007013248D1 publication Critical patent/DE602007013248D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE602007013248T 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie Active DE602007013248D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie
PCT/IB2007/003300 WO2008012693A2 (en) 2006-07-25 2007-07-25 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Publications (1)

Publication Number Publication Date
DE602007013248D1 true DE602007013248D1 (de) 2011-04-28

Family

ID=37026080

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006015180T Active DE602006015180D1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie
DE602007013248T Active DE602007013248D1 (de) 2006-07-25 2007-07-25 Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006015180T Active DE602006015180D1 (de) 2006-07-25 2006-07-25 Rekombinanter Mycobakteriumstamm, der ein FAP Protein aus Mycobakterium unter der Kontrolle eines Promotors, der unter hypoxischen Konditionen aktiv ist, exprimiert, und dessen Verwendung zur Tumortherapie

Country Status (10)

Country Link
US (2) US20090304637A1 (de)
EP (2) EP1882741B1 (de)
JP (1) JP2009544305A (de)
AT (2) ATE472602T1 (de)
CA (1) CA2658713A1 (de)
DE (2) DE602006015180D1 (de)
DK (1) DK1882741T3 (de)
ES (1) ES2347812T3 (de)
HK (1) HK1112753A1 (de)
WO (1) WO2008012693A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (en) * 2006-12-04 2008-11-20 Bacilligen, Inc. Novel immunotherapeutic mycobacteria, pharmaceutic formulations and uses thereof
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
EP2882461A4 (de) * 2012-08-10 2016-08-17 Sloan Kettering Inst Cancer Vorhersage der blasenkrebsreaktion auf bcg
WO2016026453A2 (zh) * 2014-08-20 2016-02-25 北京百诺奇生物科技有限公司 一种检测样品中靶核酸的试剂盒及检测方法
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
EP1523331B1 (de) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutisches vakzin gegen tuberkulosis
DK2206514T3 (da) * 2003-10-16 2014-04-22 Univ California Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
DE602004028506D1 (de) * 2003-12-02 2010-09-16 Pasteur Institut Neuer mit sars verbunden coronavirus stamm und seine verwendungen

Also Published As

Publication number Publication date
JP2009544305A (ja) 2009-12-17
WO2008012693A2 (en) 2008-01-31
EP1882741A1 (de) 2008-01-30
WO2008012693A3 (en) 2008-04-24
ES2347812T3 (es) 2010-11-04
HK1112753A1 (en) 2008-09-12
ATE502110T1 (de) 2011-04-15
EP2049667B1 (de) 2011-03-16
DK1882741T3 (da) 2010-10-11
CA2658713A1 (en) 2008-01-31
EP1882741B1 (de) 2010-06-30
US20120156169A1 (en) 2012-06-21
DE602006015180D1 (de) 2010-08-12
EP2049667A2 (de) 2009-04-22
US20090304637A1 (en) 2009-12-10
ATE472602T1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
WO2018026819A3 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA113712C2 (xx) Антитіло до fap і способи його застосування
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
DE602007013248D1 (de) Rekombinanter mycobakterienstamm zur durch einen bei hypoxie aktiven promotor gesteuerten expression eines mykobakteriellen fap-proteins und seine anwendung zur krebstherapie
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EP3533877A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
NZ704269A (en) Rspo3 binding agents and uses thereof
MX2009009146A (es) Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2014004719A3 (en) Chimeric peptide comprising an extracellular matrix protein together with an|antimicrobial peptide for use as a scaffold in wound dressing
MX2015005253A (es) Metodo novedoso para tratar el daño a la medula espinal utilizando el fragmento de hmgb1.
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
EP4311577A3 (de) Metalloenzyminhibitorverbindungen
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
EP3909975A4 (de) Neuartiges polypeptid und therapeutische verwendungen davon
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s